Quote | Monopar Therapeutics Inc. (NASDAQ:MNPR)
Last: | $0.655 |
---|---|
Change Percent: | 5.22% |
Open: | $0.69 |
Close: | $0.655 |
High: | $0.72 |
Low: | $0.6501 |
Volume: | 150,308 |
Last Trade Date Time: | 04/17/2024 03:00:00 am |
News | Monopar Therapeutics Inc. (NASDAQ:MNPR)
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MN...
2024-04-16 08:18:43 ET More on Monopar Therapeutics Monopar files patent protecting MNPR-101 radiopharma optimization findings Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Monopar Therapeutics Historical earnings...
Message Board Posts | Monopar Therapeutics Inc. (NASDAQ:MNPR)
Subject | By | Source | When |
---|---|---|---|
$1.40 Not nice. | willlbone | investorshub | 03/28/2023 3:52:30 PM |
$4+ nice | wesley_ | investorshub | 11/08/2022 9:35:40 PM |
Monopar Announces Completion of Phase 2b Enrollment and | subslover | investorshub | 10/05/2022 1:28:03 PM |
Well not looking great at present. However | Condors rugby | investorshub | 02/23/2021 2:47:53 PM |
With a price target of 49 and extremely | Condors rugby | investorshub | 02/12/2021 4:46:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MN...
WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused o...
WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has filed a provisional patent application pertaining to the recent adva...